Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,135 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo solution Clear all
Completed Phase 3 Interventional Results available

Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

NCT03539887
View directory record Official record
Conditions
Suicidal Ideation, Depression, Alcohol Abuse
Interventions
Intranasal ketamine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Results available

Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery

NCT01450007
View directory record Official record
Conditions
Shoulder Injury
Interventions
Ropivacaine, Dexamethasone, Normal saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

NCT03533114
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
JZP-258, Placebo Oral Solution
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 18, 2026, 5:42 AM EDT
Recruiting Phase 2 Interventional

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

NCT06949800
View directory record Official record
Conditions
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions
EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 18, 2026, 5:42 AM EDT
Not listed Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

NCT02833792
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Human Mesenchymal Stem Cells and Lactated Riunger's Solution, Placebo
Drug · Other
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BRIDGE Percutaneous Nerve Stimulation for Cesarean Delivery Pain Control

NCT04365465
View directory record Official record
Conditions
Opioid-use Disorder, Pain, Postoperative
Interventions
NSS-2 Bridge, Inactive NSS-2 Bridge, Active control
Device · Other
Lead sponsor
Grace Lim, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Increased IV Hydration on Nulliparous Women Undergoing an Induction of Labor

NCT02989571
View directory record Official record
Conditions
Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions
Intravenous normal saline administered at 250ml/hr, Intravenous normal saline administered at 125ml/hr
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

NCT00953524
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA), Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
15
States / cities
Hoover, Alabama • Chandler, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Not applicable Interventional

Normal Saline Use With Suctioning

NCT02612961
View directory record Official record
Conditions
Tracheostomy
Interventions
3mL of normal saline from the pink sodium chloride bullet, Sham Comparator of 3mL normal saline
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis

NCT00097773
View directory record Official record
Conditions
Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Interventions
Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 12 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

NCT02929823
View directory record Official record
Conditions
Corneal Epithelial Disorders
Interventions
High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
19
States / cities
Little Rock, Arkansas • Glendora, California • Lancaster, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 3 Interventional

Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)

NCT00009646
View directory record Official record
Conditions
Infant, Very Low Birth Weight, Infant, Premature, Ductus Arteriosus, Patent
Interventions
Indomethacin, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
2 Hours to 6 Hours
Enrollment
1,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
9
States / cities
Birmingham, Alabama • Palo Alto, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 18, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Results available

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

NCT03490942
View directory record Official record
Conditions
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Interventions
Glucagon, Placebo
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
21 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

NCT01590446
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Normal Saline
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
22 Years to 45 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

NCT00853970
View directory record Official record
Conditions
Pain, Inflammation
Interventions
Bromfenac Ophthalmic Solution, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 18, 2026, 5:42 AM EDT
Recruiting Phase 2 Interventional

Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty

NCT06234631
View directory record Official record
Conditions
Knee Replacement Surgery, Osteoarthritis, Knee
Interventions
Epidiolex oral solution, Placebo
Drug · Other
Lead sponsor
Chad Brummett
Other
Eligibility
18 Years to 80 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

NCT00267202
View directory record Official record
Conditions
Allergic Asthma
Interventions
Placebo, Omalizumab, Immunotherapy
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 18, 2026, 5:42 AM EDT
Terminated Phase 3 Interventional

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT01697072
View directory record Official record
Conditions
Gastric Cancer
Interventions
Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 18, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

NCT05579639
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
Xylitol, Placebo
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Months to 25 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 5:42 AM EDT
Recruiting Phase 3 Interventional

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

NCT06281977
View directory record Official record
Conditions
Ventricular Tachycardia, Ventricular Arrhythmias, Ventricular Fibrillation, Recurrent Ventricular Tachycardia
Interventions
Dexmedetomidine, Normal saline
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis

NCT01320553
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
SPARC1102 I, SPARC1102 II, SPARC1102 III, Vehicle
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
10 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 18, 2026, 5:42 AM EDT
Not listed Phase 1 Interventional

Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution

NCT00260767
View directory record Official record
Conditions
HIV
Interventions
HEC placebo gel
Drug
Lead sponsor
Biosyn
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2005 · Synced Oct 18, 2026, 5:42 AM EDT
Terminated Phase 3 Interventional

Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

NCT01956812
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Pancreatic Cancer
Interventions
IMMU-107, placebo, Gemcitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
42
States / cities
Gilbert, Arizona • Duarte, California • Long Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 18, 2026, 5:42 AM EDT